Literature DB >> 11777999

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.

Wayne L Chandler1, Srdjan Jelacic, Daniel R Boster, Marcia A Ciol, Glyn D Williams, Sandra L Watkins, Takashi Igarashi, Phillip I Tarr.   

Abstract

BACKGROUND: The hemolytic-uremic syndrome is a thrombotic complication of Escherichia coli O157:H7 infection. It is not known whether the coagulation abnormalities precede, and potentially cause, this disorder.
METHODS: In 53 children infected with E. coli O157:H7, we measured a panel of markers indicating activation of the clotting cascade and renal function within four days after the onset of illness. These markers were measured again in as many as possible of the 16 children in whom the hemolytic-uremic syndrome developed.
RESULTS: The children in whom the hemolytic-uremic syndrome subsequently developed had significantly higher median plasma concentrations of prothrombin fragment 1+2, tissue plasminogen activator (t-PA) antigen, t-PA-plasminogen-activator inhibitor type 1 (PAI-1) complex, and D-dimer than children with uncomplicated infection. These abnormalities preceded the development of azotemia and thrombocytopenia. When the hemolytic-uremic syndrome developed, the urinary concentrations of beta2-microglobulin and N-acetyl-beta-glucosaminidase rose significantly (P=0.03 for both increases); the plasma concentrations of t-PA antigen, t-PA-PAI-1 complex, D-dimer, and plasmin-antiplasmin complex also increased significantly. The concentration of t-PA antigen correlated with that of the t-PA-PAI-1 complex in a linear regression model (squared correlation coefficient, 0.80; P<0.001).
CONCLUSIONS: In the hemolytic-uremic syndrome, thrombin generation (probably due to accelerated thrombogenesis) and inhibition of fibrinolysis precede renal injury and may be the cause of such injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777999     DOI: 10.1056/NEJMoa011033

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

1.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Authors:  Fadila Guessous; Marek Marcinkiewicz; Renata Polanowska-Grabowska; Sudawadee Kongkhum; Daniel Heatherly; Tom Obrig; Adrian R L Gear
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome.

Authors:  Andrea V Page; Phillip I Tarr; Sandra L Watkins; Nimerta Rajwans; Tania N Petruzziello-Pellegrini; Philip A Marsden; Kevin C Kain; W Conrad Liles
Journal:  J Infect Dis       Date:  2013-06-24       Impact factor: 5.226

Review 5.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 6.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

8.  Cardiac ischemia during hemolytic uremic syndrome.

Authors:  Meena Thayu; Wayne L Chandler; Srdjan Jelacic; Carrie A Gordon; Geoffrey L Rosenthal; Phillip I Tarr
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

9.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Authors:  Alessandra Gianviti; Alberto E Tozzi; Laura De Petris; Alfredo Caprioli; Lucilla Ravà; Alberto Edefonti; Gianluigi Ardissino; Giovanni Montini; Graziella Zacchello; Alfonso Ferretti; Carmine Pecoraro; Tommaso De Palo; Angela Caringella; Maurizio Gaido; Rosanna Coppo; Francesco Perfumo; Nunzia Miglietti; Ilse Ratsche; Rosa Penza; Giovambattista Capasso; Silvio Maringhini; Salvatore Li Volti; Carmen Setzu; Marco Pennesi; Alberto Bettinelli; Leopoldo Peratoner; Ivana Pela; Elio Salvaggio; Giuliana Lama; Salvatore Maffei; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

10.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.